AstraZeneca Slaps Sun Pharma Over Nexium IV Generic

By Liz McKenzie

Law360, New York (March 02, 2010, 4:25 PM ET) -- AstraZeneca AB has hit generic-drug maker Sun Pharma Global Inc. with a patent suit over its plan to market a generic formulation of AstraZeneca’s intravenous acid reflux disease treatment Nexium IV.

Swedish pharmaceutical heavyweight AstraZeneca lodged the patent infringement complaint Monday in the U.S. District Court for the Eastern District of Michigan after receiving notification of Sun Pharma’s abbreviated new drug application, which claims the patents covering Nexium IV are invalid.

AstraZeneca says Sun Pharma has asked the U.S. Food and Drug Administration for approval to...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles